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University of Copenhagen and 5) Novo Nordisk Foundation Centre for Biosustainability, The Technical University of Denmark, Hørsholm, DenmarkAbstractIn patients with primary ciliary dyskinesia (PCD), impaired mucociliary clearance leads to an accumulation of secretions in the airways and
susceptibility to repeated bacterial infections. The primary aim of this study was to investigate the bacterial ﬂora in non-chronic and chronic
infections in the lower airways of patients with PCD. We retrospectively reviewed the presence of bacteria from patients with PCD during an
11-year period and genotyped 35 Pseudomonas aeruginosa isolates from 12 patients with chronic infection using pulsed-ﬁeld gel
electrophoresis. We identiﬁed 5450 evaluable cultures from 107 patients with PCD (median age 17 years, range 0–74 years) (median age
at diagnosis 7.8 years, range 0–63 years). Haemophilus inﬂuenzae was the most frequent microorganism. Other common pathogens were
P. aeruginosa, Streptococcus pneumoniae, Moraxella catarrhalis and Staphylococcus aureus. The number of patients colonized with
P. aeruginosa at least once varied from 11 to 44 patients (15–47%) annually, and 42 patients (39%) met the criteria for chronic infection
at least once. Pseudomonas aeruginosa was more frequently isolated in teenagers and adults than children (p 0.02) and the prevalence was
signiﬁcantly lower in patients with preschool (<6 years) PCD diagnosis (p 0.04). Ten out of 12 patients (83%) were chronically infected
with a unique clone-type of P. aeruginosa. No sharing of clone-types or patient-to-patient transmission was observed. In conclusion, PCD
patients were infected by a unique set of bacteria acquired in an age-dependent sequence. Pseudomonas aeruginosa frequently colonizes
the lower respiratory tract and the incidence of chronic infection was higher than previously reported.
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rights reserved.
Keywords: Ciliary motility disorders, Kartagener’s syndrome, mucociliary clearance, Pseudomonas aeruginosa, pulse-ﬁeld gel electrophoresis
Original Submission: 2 June 2015; Revised Submission: 21 August 2015; Accepted: 21 August 2015
Editor: F. Allerberger
Article published online: 2 September 2015Corresponding author: M.C. Alanin, Department of Otolaryn-
gology– Head and Neck Surgery and Audiology, Copenhagen
University Hospital, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen,
Denmark
E-mail: mikkel.christian.alanin.01@regionh.dkIntroductionPrimary ciliary dyskinesia (PCD) is an autosomal recessive
genetic disease caused by mutations in genes involved in ciliary
structure and function. To date, mutations in 31 genesClinical Microbiology and Infection © 2015 European Society of Ccovering approximately 60% of the PCD population have been
described [1].
Normal ciliary movements play an integral part in the innate
immune system and a critical role in airway defence. Due to
impaired mucociliary clearance patients with PCD are predis-
posed to repeated or chronic infections of the upper and lower
airways, which may lead to decreased lung function and bron-
chiectasis. Over time, 20% of PCD patients may develop end-
stage lung disease [2].
Pseudomonas aeruginosa occasionally colonizes the lungs of
patients with PCD and may cause destruction of the same
character as demonstrated in patients with cystic ﬁbrosis (CF).
However, the pattern of bacterial ﬂora in patients with PCDClin Microbiol Infect 2015; 21: 1093.e1–1093.e7
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
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ogens may contribute to pulmonary disease in PCD, including
Staphylococcus aureus, Haemophilus inﬂuenzae, Moraxella catar-
rhalis and Streptococcus pneumoniae [4,5]. As the available
microbiological data in patients with PCD is incomplete, the
primary aim of this study was to describe the general bacterial
ﬂora longitudinally, including the ﬂora of chronic infections in
the lower respiratory tract in patients with PCD, and to
examine how the ﬂora may change with patients’ age.Materials and methodsStudy design and patients
We performed a retrospective study where we investigated the
bacterial ﬂora including the ﬂora of chronic infections in the
lower airways of patients with PCD during an 11-year period
(January 2002 to December 2012). All Danish PCD patients are
diagnosed and treated at the Danish PCD Centre at Rig-
shospitalet in Copenhagen. Inclusion criteria were (1) deﬁnitive
PCD diagnosis based on presentation of the characteristic
clinical phenotype and ciliary ultrastructural defects, abnormal
ciliary function or a genetic mutation recognized to cause PCD
[6] and (2) evaluable bacteriological data obtained from the
laboratory database at the Department of Clinical Microbiology
at Rigshospitalet.
General care
Patients with a diagnosis of PCD are permanently afﬁliated with
the outpatient clinic of the Danish PCD Centre and inten-
tionally appointed every third month with clinical examinations,
lung function measurement, and sputum samples. Blood sam-
ples are obtained annually for antibody measurements. Patients
visit the same outpatient facility as children with CF and follow
the same isolation strategy [7]. In brief, the isolated groups
consist of (1) patients chronically infected P. aeruginosa, (2)
patients without chronic P. aeruginosa infection including pa-
tients with intermittent P. aeruginosa colonization and (3) pa-
tients harbouring other Gram-negative bacteria.
Antibiotic treatment
Patients with positive lower respiratory tract samples are
treated promptly even without the presence of clinical symp-
toms, and when P. aeruginosa is the disease-causing pathogen,
patients are treated with colistin inhalation and oral ciproﬂox-
acin for 21 days in patients without chronic P. aeruginosa
infection. Patients with chronic P. aeruginosa infection are
additionally treated every third month with a 2-week intrave-
nous antibiotic course. Prophylactic antibiotic treatment is not
used.Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectBacteriological examination
Bacterial data were based on sputum samples or secretions
obtained by endolaryngeal suction cultured at 37°C on standard
agar media for 2 to 5 days. The media included a Sabouraud
plate, a 7% NaCl plate, a ‘Blue plate’ (modiﬁed Conradi Dri-
galski’s medium; State Serum Institute, Copenhagen, Denmark)
selective for Gram-negative rods and non-selective media
including 5% Danish blood agar and chocolate agar [7,8]. Gram-
stained smears were examined using microscopy.
Lung infection status
We have extrapolated criteria and deﬁnitions developed for CF
to the lung infection status of patients with PCD [9,10]. With
modiﬁed ‘CF Leeds criteria’ [11] we deﬁned the lung infection
status as:
 Chronic infection, when >50% of the preceding 12 months’
cultures were positive for the speciﬁc pathogen;
 Intermittent colonization, when 50% or less of the preceding
12 months’ cultures were positive for the speciﬁc pathogen;
 Free of colonization and infection, when no growth has
occurred in the lungs in the previous 12 months.
In order to be categorized according to these criteria, the
patient should provide at least four samples of secretions from
the lower airways during 1 year.
Spirometry
We calculated the median lung function for bacteriologically
evaluable patients in 2012. For the remaining patients, we
included the spirometry from the year of their latest evaluable
bacteriological examination. Forced expiratory volume (FEV1%)
predicted and forced volume capacity (FVC %) predicted as per
American Thoracic Society standards [12].
Precipitins
Speciﬁc precipitating antibodies against P. aeruginosa were
measured annually using crossed immunoelectrophoresis at the
Department of Clinical Microbiology, Rigshospitalet. Normal
values are 0–1, and 2 precipitins is considered abnormal
[13–15]. We did have an exception relative to the modiﬁed ‘CF
Leeds criteria’: If a patient had more than one, but less than four
positive bacteriological samples in combination with abnormal
precipitins, we classiﬁed the patient as chronically infected.
Pulsed-ﬁeld gel electrophoresis
Stored P. aeruginosa isolates were genotyped using pulsed-ﬁeld
gel electrophoresis (PFGE) as described previously [7]. The
PFGE bands were evaluated visually according to the guidelines
of Tenover et al. [16]. Isolates with differences in up to twoious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1093.e1–1093.e7
TABLE 1. Patient characteristics and the number of
respiratory samples each year
Year
PCD patients
included
(males)a
Total number of representative
samples for bacteriological
culture each year (per patient
median, range) n ‡4 samplesb
2002 56 (27) 345 (6, 1–17) 38
2003 71 (35) 439 (6, 1–25) 50
2004 74 (37) 482 (6, 1–32) 51
2005 75 (36) 455 (5, 1–25) 47
2006 78 (36) 421 (4, 1–22) 53
2007 92 (44) 496 (4, 1–23) 55
2008 91 (42) 535 (5, 1–21) 55
2009 94 (43) 556 (5, 1–19) 65
2010 94 (45) 561 (5, 1–15) 70
2011 95 (46) 573 (5, 1–16) 67
2012 99 (47) 587 (5, 1–16) 69
aTo be included a patient should have at least one respiratory sample from the
lower airways that year.
bThese patients can be classiﬁed according to the ‘Cystic Fibrosis Leeds criteria’.
CMI Alanin et al. Longitudinal study of bacteriology in PCD 1093.e3bands were considered identical. Both inter-patient and intra-
patient relatedness were assessed.
Epidemiological terms
We used the period prevalence rate (PePR) to deﬁne the
percentage of patients who harboured the bacteria in question
in one or more examinations during a calendar year. The period
prevalence rate for chronic infection (PePRchr) refers to the
percentage of patients who could be classiﬁed as chronically
infected during a calendar year according to our criteria.
Statistics
Statistical Analysis Software (SAS) version 9.3 was used for
statistical analysis. Logistic regression using generalized esti-
mating equations to take the clustered nature of the data into
account was used to compare age group and age at diagnosis
with the frequency of selected bacteria in the lower airways.
Ethics
The study was approved by the local ethics committee (H-1-
2013-032).ResultsA total of 107 patients with PCD were included in the study (50
male and 57 female, median age 17 years, range 0–74 years).
The median age at diagnosis was 7.8 years (range 0–63 years).
A total of 5450 samples represented the lower airways (veriﬁed
by microscopy). The median number of samples per patient per
year was 5 (range 4–6). The patients had variable follow-up
periods; the median follow up was 9 years (range 1–11
years). A median of 55 patients (range 38–70) per year were
eligible for categorization according to lung infection status
using the ‘CF Leeds criteria’ (Table 1). In all, 857 precipitin
measurements were available in 103 out of the 107 patients
(96%). The median precipitin was 1, range 0–35.
Spirometry was evaluable in 99 patients (93%). The median
FEV1% predicted was 77% (range 22–127%) and the median
FVC% predicted was 93% (range 51–141%). Eight patients had
no spirometry available because they were too young to
comply.
Non-capsulate H. inﬂuenzae
Haemophilus inﬂuenzae was the most frequently isolated bac-
terium in our cohort, with a median PePR of 62% (range
46–80%). Annually, 7 to 23 patients (8–31%) were chronically
infected. A median of one patient (range 0–5) had simultaneous
chronic H. inﬂuenzae and P. aeruginosa infection. There was a
negative association between the occurrence of H. inﬂuenzaeClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infeand age, and the incidence differed signiﬁcantly across age
groups, p 0.002 (Fig. 1).
Pseudomonas aeruginosa
The median PePR was 32% (range 15–47), similar to 11–44
patients being intermittently colonized annually. Positive
P. aeruginosa isolates originated from sputum samples in 92%
and from secretions obtained by endolaryngeal suction in 8%.
Forty-two patients (39%) met the criteria for chronic
P. aeruginosa infection at least once during the study period and
four of these were infected with the mucoid phenotype. Fig. 2
displays the course of infection in patients with chronic
P. aeruginosa infection. The deﬁnition of chronic infection was
based on culture = the modiﬁed ‘CF Leeds criteria’ in 30 pa-
tients (71%) and on a combination of precipitins and cultures in
the remaining 12 patients (29%). A median of 4 (range 1–8)
new patients became chronically infected each year, and an
average of 11 patients (13%) met the deﬁnition of chronic
infection annually. The median age at ﬁrst chronic infection was
20 years (range 5–67 years). Chronic infection was cleared for
a minimum of 1 year in 29 out of the 42 patients (69%); 20
patients were free of infection and nine continued as inter-
mittently colonized. All patients were evaluable with at least
four representative samples or a combination of sputum sam-
ples and precipitins in the year following chronic infection.
During the study, 74 of 107 patients (69%) had one or more
sputum samples positive for P. aeruginosa. The incidence of
P. aeruginosa differed signiﬁcantly across age groups p 0.02
(Fig. 1). We hypothesized that early PCD diagnosis was asso-
ciated with a lower incidence of P. aeruginosa. The overall
prevalence of P. aeruginosa in patients with a conﬁrmed diag-
nosis before school age (<6 years) was 9% relative to 20% in
patients with later diagnosis. The difference was statistically
signiﬁcant (p 0.04).ctious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1093.e1–1093.e7
FIG. 1. Percentage of positive samples with Pseudomonas aeruginosa,
Haemophilus inﬂuenzae, Staphylococcus aureus, Moraxella catarrhalis and
Achromobacter xylosoxidans in patients with primary ciliary dyskinesia
according to age group. Patients were followed from 2002 to 2012.
Children: 0–12 years, n = 62; teenagers and young adults: 13–25 years,
n = 54; adults >25 years, n = 38. A patient can appear in more than one
age group. *p <0.05.
1093.e4 Clinical Microbiology and Infection, Volume 21 Number 12, December 2015 CMIPFGE
We genotyped 35 P. aeruginosa isolates from 12 patients using
PFGE. The median timespan between ﬁrst and last isolates in each
individualwas 2.0 years (range 0.4–3.6 years). Intra-patient genetic
relatedness of P. aeruginosa isolates was found in 10 of 12Year
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FIG. 2. Lexis diagram showing the course of Pseudomonas aeruginosa
infection in 42 patients with primary ciliary dyskinesia who qualiﬁed as
chronically infected at least once between 2002 and 2012. Courses are
displayed from the ﬁrst evaluable sample until the last observation in
2012. All but one patient (small dots) was evaluable. Chronic infection
was based on modiﬁed ‘Cystic Fibrosis Leeds criteria’.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectchronically infected patients (83%). In two patients, we observed a
shift in clone-type. We observed no sharing of clone-types be-
tween the 12 PCDpatients and no patient-to-patient transmission.
We provide an example of genetic relatedness and an example of a
change in clone-type in Supporting Information online.
Other bacteria
The number of patients with PCD colonized and chronically
infected with Staphylococcus aureus, Streptococcus pneumoniae,
Achromobacter xylosoxidans, Aspergillus fumigatus and M. catarrhalis
is given in Supporting Information online. Fig. 1 illustrates how
different Gram-negative bacteria vary by age and reports if the
incidence differs signiﬁcantly (p <0.05) across age groups.
Non-tuberculous mycobacteria (Mycobacterium abscessus)
was isolated once from a single patient in 2010.DiscussionIn this comprehensive, retrospective study we present an
overview of the bacterial ﬂora from the lower respiratory tract
in patients with PCD followed during an 11-year period in the
Danish national PCD Centre. We also present novel data
concerning the genetic relatedness of P. aeruginosa strains in
individual patients with PCD who have chronic infections.
In patients with PCD, the progression of lung disease may
result from continuous pulmonary infections, inﬂammation and
a change in the lower airway pathogens over time. Haemophilus
inﬂuenzae and M. catarrhalis dominate in children, whereas
P. aeruginosa is more common in teenagers and adults. This
infection pattern resembles patients with CF, who are infected
by a unique set of bacteria acquired in an age-dependent
sequence; early infections are most frequently caused by
Staphylococcus aureus and H. inﬂuenzae, and later P. aeruginosa
and other Gram-negative bacteria take over [17]. However, in
CF the diversity of bacteria decrease with age [18], which
contrasts with our results (Fig. 1), and the pathogens described
in the present study seem consistent with the pathogens
demonstrated in patients with non-CF bronchiectasis [19,20].
Pseudomonas aeruginosa frequently colonizes the lower respi-
ratory tract in patients with PCD and for the ﬁrst time we found a
signiﬁcantly increased incidence with increasing age, which is only
partially shown in previous studies [2,4]. The observation that
early PCD diagnosis is correlated with a signiﬁcant lower preva-
lence of P. aeruginosa is new. Chronic infection was observed in
39% of all patients at least once. This is markedly higher than
previously reported; Maglione et al. [3] reported chronic infection
in 8 out of 158 (5%) children with PCD. The difference may be
because of differences in age, frequency of sputum sample
collection and the criteria used to deﬁne chronic infection.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1093.e1–1093.e7
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seem valid, as 83% of chronically infected patients harboured the
same clone-type for years. Another explanation for the higher
rate of chronic infection is the possibility of cross-infections from
other PCD patients; however, genetically unrelated isolates were
found in the 12 patients, indicating a lack of transmission between
patients and a successful isolation strategy.
Importantly, part of the sputum data from 54 children from
the present study was also included in the above-mentioned
study by Maglione et al. [3], which is a limitation. However,
there are several major differences between the two studies.
Maglione et al. focused mainly on nutrition and lung function.
Our study focuses on the bacterial ﬂora from the lower airways
veriﬁed by microscopy in a national centre with well-
established treatment regimens in the entire study period.
Maglione et al. did not exclude samples with only oral ﬂora and
included children from different European centres, which may
have different treatment regimens. Further, Maglione et al. did
not correlate bacterial ﬂora with age or age at diagnosis, or
discuss deﬁnitions of infection status, which are novel analyses.
The observed chronic infection pattern with intermediate
periods without infection may be unique for PCD and different
from that observed in CF. The reason for this difference may be
that patients with PCD have a milder lung disease compared with
CF patients, which is exempliﬁed by a later age at diagnosis 7.8
years versus 6–12 months in CF. In CF, eradication of
P. aeruginosa from chronically infected lungs is rarely achieved
[21]. The observed infection pattern in PCD may support the
possibility of a non-pulmonary bacterial reservoir for repeated
pulmonary infections, which may be the upper airways [22] as in
patients with CF [23–25]. Future studies are needed to examine
a potential beneﬁt of sinus surgery in patients with PCD.
Our results indicate that P. aeruginosa is a common and
important pathogen in PCD, colonizing 15–47% of patients
annually. This is supported by Davis et al. [5], who found
P. aeruginosa in the lungs of 9% of children with PCD in a cross-
sectional study. However, chronic lung infection with
P. aeruginosa may have a smaller impact on lung function in PCD
patients than in CF patients, which is in agreement with pre-
vious studies [3,5,26] that found no correlation between lower
respiratory tract pathogens and lung function.
In agreement with previous studies [2–5,27], non-capsulate
H. inﬂuenzae was the most frequently isolated bacterium.
Chronic infection was common, but most patients were not
chronically infected in successive years, suggesting an effective
treatment regimen. However, to date no controlled trials
examining the effect of antibiotic eradication therapy in PCD
patients have been published [6].
Non-tuberculous mycobacteria were isolated from only one
patient during the study period, which contradicts previousClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infereports by Davis et al. [5], who found non-tuberculous myco-
bacteria in 3% of children with PCD, and Noone et al. [2], who
isolated non-tuberculous mycobacteria in 10% of adult PCD
patients. A possible explanation for the low prevalence of non-
tuberculous mycobacteria may be a limited diagnostic focus on
these bacteria until recent years in our centre.
We ﬁnd it relevant that a uniform deﬁnition of infection
status was established in patients with PCD, as this could be
useful concerning strategies for antibiotic therapy, cohort-
isolation, and for publication purposes and comparative clin-
ical studies. We adopted deﬁnitions established in CF to deﬁne
lung infection status in PCD, which may not be optimal.
Chronic infection implies persistence of the bacteria in the
focus (lungs/sputum). It may seem contradictory that some
patients categorized with chronic infection are later considered
not chronically infected. Hence, it may be beneﬁcial to intro-
duce a heritable component to the criteria as suggested in CF
by Green et al. [28], where persistent infection is deﬁned as
three consecutive years of culture data with at least one posi-
tive culture in at least two of the three years. Another limita-
tion is the exclusive use of standard culture techniques, which
may underestimate the diversity of potential pathogens from
the lower airways [18]. However, using microscopy on all
samples ensures representation from the lower airways.
The levels of precipitins against P. aeruginosa are used in our
centre because serology may be more sensitive than cultures in
detecting early chronic respiratory tract infections [17]. How-
ever, as in the case of vaccination, antibodies are still measur-
able long after the antigen/bacteria have been eliminated
(immunological memory), so detection of antibodies in culture-
negative patients where the bacteria have been successfully
eliminated by antibiotics is not indicative of actual chronic
infection. The use of precipitins in patients with PCD therefore
requires further research.
Here, we present a comprehensive study of a national cohort
of 107 Danish patients with PCD including extensive longitudinal
microbiological follow up for 11 years, allowing new insights into
our understanding and deﬁnition of bacterial colonization and
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